Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681299 · ClinicalTrials.gov registry record · Phase 4
Effects of GH and Lirglutide on AgRP
A Phase 4 study of Healthy and Growth Hormone Deficiency, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05681299 is a Phase 4 study of Healthy and Growth Hormone Deficiency that is actively recruiting participants, run by Columbia University. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05681299, a Phase 4 study of Healthy and Growth Hormone Deficiency, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG growth hormone and lirglutide
- DRUG growth hormone
- DRUG liraglutide
Study Locations (1)
New York
- Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05681299
The ClinicalTrials.gov registry entry for NCT05681299 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05681299 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05681299 about?
NCT05681299 is a clinical study titled "Effects of GH and Lirglutide on AgRP". This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglu...
What is the current status of trial NCT05681299?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2023-05-01. Estimated completion is 2028-04-30.
What conditions does trial NCT05681299 study?
This clinical trial studies the following conditions: Healthy, Growth Hormone Deficiency.
What interventions are being tested in trial NCT05681299?
The interventions under investigation include: Placebo (DRUG), growth hormone and lirglutide (DRUG), growth hormone (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT05681299?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05681299 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
-
VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.